The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Acquired Orphan Blood Diseases Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack of red blood cells in blood, which in turn results in a decrease in platelet numbers. This decrease in platelet number causes anemia and thrombosis.
The global Acquired Orphan Blood Diseases Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Acquired Orphan Blood Diseases Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Acquired Orphan Blood Diseases Therapeutics market. Medication, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Bone Marrow Transplant segment is estimated at % CAGR for the next seven-year period.
Soliris (eculizumab) is a perfect example of a successful orphan blood disease drug. PNH is a potentially life-threatening blood disease, characterised by severe anemia caused by the destruction of red blood cells in the bloodstream. Bone marrow transplants can provide a cure, but the high risk procedure is suitable for only a few patients. Treatment methods include blood transfusions, iron therapy, and growth factors, but monoclonal antibody
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acquired Orphan Blood Diseases Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acquired Orphan Blood Diseases Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acquired Orphan Blood Diseases Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acquired Orphan Blood Diseases Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acquired Orphan Blood Diseases Therapeutics covered in this report include Alexion Pharmaceuticals, Amgen, Celgene, Eli Lilly, Sanofi, GlaxoSmithKline, Cyclacel Pharmaceuticals, Onconova Therapeutics and Incyte, etc.
The global Acquired Orphan Blood Diseases Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alexion Pharmaceuticals
Amgen
Celgene
Eli Lilly
Sanofi
GlaxoSmithKline
Cyclacel Pharmaceuticals
Onconova Therapeutics
Incyte
CTI BioPharma
Global Acquired Orphan Blood Diseases Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acquired Orphan Blood Diseases Therapeutics market, Segment by Type:
Medication
Bone Marrow Transplant
Blood Transfusion
Immunotherapy
Global Acquired Orphan Blood Diseases Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acquired Orphan Blood Diseases Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack of red blood cells in blood, which in turn results in a decrease in platelet numbers. This decrease in platelet number causes anemia and thrombosis.
The global Acquired Orphan Blood Diseases Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Acquired Orphan Blood Diseases Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Acquired Orphan Blood Diseases Therapeutics market. Medication, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Bone Marrow Transplant segment is estimated at % CAGR for the next seven-year period.
Soliris (eculizumab) is a perfect example of a successful orphan blood disease drug. PNH is a potentially life-threatening blood disease, characterised by severe anemia caused by the destruction of red blood cells in the bloodstream. Bone marrow transplants can provide a cure, but the high risk procedure is suitable for only a few patients. Treatment methods include blood transfusions, iron therapy, and growth factors, but monoclonal antibody
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Acquired Orphan Blood Diseases Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Acquired Orphan Blood Diseases Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Acquired Orphan Blood Diseases Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Acquired Orphan Blood Diseases Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Acquired Orphan Blood Diseases Therapeutics covered in this report include Alexion Pharmaceuticals, Amgen, Celgene, Eli Lilly, Sanofi, GlaxoSmithKline, Cyclacel Pharmaceuticals, Onconova Therapeutics and Incyte, etc.
The global Acquired Orphan Blood Diseases Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alexion Pharmaceuticals
Amgen
Celgene
Eli Lilly
Sanofi
GlaxoSmithKline
Cyclacel Pharmaceuticals
Onconova Therapeutics
Incyte
CTI BioPharma
Global Acquired Orphan Blood Diseases Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Acquired Orphan Blood Diseases Therapeutics market, Segment by Type:
Medication
Bone Marrow Transplant
Blood Transfusion
Immunotherapy
Global Acquired Orphan Blood Diseases Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Acquired Orphan Blood Diseases Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Acquired Orphan Blood Diseases Therapeutics
1.1 Acquired Orphan Blood Diseases Therapeutics Market Overview
1.1.1 Acquired Orphan Blood Diseases Therapeutics Product Scope
1.1.2 Acquired Orphan Blood Diseases Therapeutics Market Status and Outlook
1.2 Global Acquired Orphan Blood Diseases Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Acquired Orphan Blood Diseases Therapeutics Market Size by Region (2018-2029)
1.4 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Acquired Orphan Blood Diseases Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Acquired Orphan Blood Diseases Therapeutics Market Size (2018-2029)
1.6.1 North America Acquired Orphan Blood Diseases Therapeutics Market Size (2018-2029)
1.6.2 Europe Acquired Orphan Blood Diseases Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size (2018-2029)
1.6.4 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size (2018-2029)
2 Acquired Orphan Blood Diseases Therapeutics Market by Type
2.1 Introduction
2.1.1 Medication
2.1.2 Bone Marrow Transplant
2.1.3 Blood Transfusion
2.1.4 Immunotherapy
2.2 Global Acquired Orphan Blood Diseases Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Type (2018-2029)
3 Acquired Orphan Blood Diseases Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Acquired Orphan Blood Diseases Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Acquired Orphan Blood Diseases Therapeutics Revenue Breakdown by Application (2018-2029)
4 Acquired Orphan Blood Diseases Therapeutics Competition Analysis by Players
4.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Acquired Orphan Blood Diseases Therapeutics as of 2022)
4.3 Date of Key Players Enter into Acquired Orphan Blood Diseases Therapeutics Market
4.4 Global Top Players Acquired Orphan Blood Diseases Therapeutics Headquarters and Area Served
4.5 Key Players Acquired Orphan Blood Diseases Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Acquired Orphan Blood Diseases Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Alexion Pharmaceuticals
5.1.1 Alexion Pharmaceuticals Profile
5.1.2 Alexion Pharmaceuticals Main Business
5.1.3 Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.1.4 Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Alexion Pharmaceuticals Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.2.4 Amgen Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Amgen Recent Developments
5.3 Celgene
5.3.1 Celgene Profile
5.3.2 Celgene Main Business
5.3.3 Celgene Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.3.4 Celgene Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Eli Lilly Recent Developments
5.4 Eli Lilly
5.4.1 Eli Lilly Profile
5.4.2 Eli Lilly Main Business
5.4.3 Eli Lilly Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.4.4 Eli Lilly Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Eli Lilly Recent Developments
5.5 Sanofi
5.5.1 Sanofi Profile
5.5.2 Sanofi Main Business
5.5.3 Sanofi Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.5.4 Sanofi Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Sanofi Recent Developments
5.6 GlaxoSmithKline
5.6.1 GlaxoSmithKline Profile
5.6.2 GlaxoSmithKline Main Business
5.6.3 GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.6.4 GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 GlaxoSmithKline Recent Developments
5.7 Cyclacel Pharmaceuticals
5.7.1 Cyclacel Pharmaceuticals Profile
5.7.2 Cyclacel Pharmaceuticals Main Business
5.7.3 Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.7.4 Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Cyclacel Pharmaceuticals Recent Developments
5.8 Onconova Therapeutics
5.8.1 Onconova Therapeutics Profile
5.8.2 Onconova Therapeutics Main Business
5.8.3 Onconova Therapeutics Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.8.4 Onconova Therapeutics Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Onconova Therapeutics Recent Developments
5.9 Incyte
5.9.1 Incyte Profile
5.9.2 Incyte Main Business
5.9.3 Incyte Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.9.4 Incyte Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Incyte Recent Developments
5.10 CTI BioPharma
5.10.1 CTI BioPharma Profile
5.10.2 CTI BioPharma Main Business
5.10.3 CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Products, Services and Solutions
5.10.4 CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 CTI BioPharma Recent Developments
6 North America
6.1 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Acquired Orphan Blood Diseases Therapeutics Market Dynamics
11.1 Acquired Orphan Blood Diseases Therapeutics Industry Trends
11.2 Acquired Orphan Blood Diseases Therapeutics Market Drivers
11.3 Acquired Orphan Blood Diseases Therapeutics Market Challenges
11.4 Acquired Orphan Blood Diseases Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
